## Apo E

### Location:
- Chromosome 19
- **APOE**
  - APO E2: cys / cys
  - APO E3: cys / arg
  - APO E4: arg / arg

### Your Genotype:

<table>
<thead>
<tr>
<th>2</th>
<th>3</th>
</tr>
</thead>
</table>

The two SNPs lead to 3 possible variants for each chromosome, known as ApoE2, E3, & E4.

### Apoprotein E: CHOLESTEROL REGULATION

Apolipoprotein E (Apo E) plays a key role in lipid metabolism by helping to remove dietary cholesterol (chylomicrons and VLDL) from the bloodstream.

#### Health Implications
- The APO E2/3 genotype is common, accounting for 10-15% of most populations
- APO E2 is associated with lower LDL cholesterol and higher HDL-C, but higher triglycerides (as found in Metabolic Syndrome) compared to the other genotypes
- APO E2 also confers a lower risk of atherosclerosis, myocardial infarction, stroke, and osteoporosis, and higher antioxidant activity

#### Treatment Options
- The cholesterol-lowering effect of a low saturated fat and low cholesterol diet is least effective with E2 individuals
- Minimize high-glycemic index foods, which produce the largest triglyceride (TG) response in E2 carriers
- Dietary fiber, fish oils, and exercise generally improve the lipid profile in this genotype; fish oils reduce TGs most effectively in E2 individuals
- Alcohol may reduce LDL-C in men (neutral in women)
- E2 individuals generally respond the most favorably to statins and would therefore likely respond to statin mimetics such as inositol hexaniacinate, red rice yeast, and policosanol
- Gemfibrozil may be particularly effective at lowering TGs and total cholesterol
- HRT improves the lipid profile in this genotype, although oral estrogen may significantly increase TGs

#### Key
- **- -** Neither chromosome carries the genetic variation.
- **+ -** One chromosome (of two) carries the genetic variation.
- **+ +** Both chromosomes carry the genetic variation.

(You inherit one chromosome from each parent)

<table>
<thead>
<tr>
<th>Gene activity increased</th>
<th>Gene activity decreased</th>
</tr>
</thead>
</table>

© Genova Diagnostics · CLIA Lic. #34D0655571 · Medicare Lic. #34-8475
### CETP

<table>
<thead>
<tr>
<th>Location:</th>
<th>Chromosome 16</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAQ1B</td>
<td>Your Genotype:</td>
</tr>
</tbody>
</table>

**Health Implications**
- Taq1B genotype promotes lower CETP activity and LDL-cholesterol and higher HDL-C; LDL and HDL particle size also tends to be higher
- This Rsa1 polymorphism confers some increased cardiovascular risk, especially in women or when high triglycerides
- Protective effect of Taq1B on HDL is blunted in smokers and individuals with insulin resistance and/or obesity

**Treatment Options**
- Smoking cessation preserves protective effect of HDL
- Alcohol may further atherosclerosis risk in this RSA genotype
- Maintain optimal insulin sensitivity, body weight, and triglyceride levels

### SELE

<table>
<thead>
<tr>
<th>Location:</th>
<th>Chromosome 1q23</th>
</tr>
</thead>
<tbody>
<tr>
<td>S128R</td>
<td>Your Genotype:</td>
</tr>
</tbody>
</table>

**Health Implications**
- Increased adhesion of E-selectin leads to atherosclerosis & restenosis
- Enhanced thrombin production, increasing the risk of coagulation

**Treatment Options**
- Increase Ω-3 fatty acids, which are inversely related to E-selectin level. Avoid trans fats, which can increase levels 20%
- NFκB inhibitors reduce cytokine-induced E-selectin expression.
- Avoid smoking to decrease E-selectin expression in blood vessels
- Estrogen therapy reduces E-selectin levels post-menopausally
- Weight loss reduces E-selectin in obese individuals
### MTHFR

**5,10-methyltetrahydrofolate reductase : METHYLATION**

<table>
<thead>
<tr>
<th><strong>Location:</strong></th>
<th>Chromosome 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>C677T</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Your Genotype:</strong></td>
<td></td>
</tr>
</tbody>
</table>

5,10-methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism, facilitating the formation of methyltetrahydrofolate, a required cofactor in the remethylation of homocysteine (Hcy) to methionine.

**Health Implications**
- Heterozygosity for both 677 (−/+) and 1298 (−/+) results in 50-60% reduction in MTHFR enzyme activity, low folate status, and increased risk of elevated homocysteine (and S-adenosylhomocysteine, or SAH)
- MTHFR polymorphism-induced SAH elevations may disrupt neurotransmitter metabolism as well as synthesis of DNA, carnitine, and coenzyme Q10
- Increased risk of autism, depression, neural tube defects, cardiovascular disease, diabetic retinopathy, osteoporosis, and some cancers
- Low folate status significantly increases risk of associated disorders

**Treatment Options**
- Ensure adequate intake of folate-rich green vegetables
- Consider supplementation with folic acid (or folinic acid or 5-methyltetrahydrofolate), vitamins B2, B3, B6 (pyridoxal 5-phosphate), B12 (or methylcobalamin), and betaine (trimethylglycine)

### GNB3

**Guanine Nucleotide-binding Protein ²-3 : HYPERTENSION**

<table>
<thead>
<tr>
<th><strong>Location:</strong></th>
<th>Chromosome 12</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>C825T</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Your Genotype:</strong></td>
<td></td>
</tr>
</tbody>
</table>

G-proteins regulate cell-to-cell signal transduction in ~80% of cellular receptors. GNB3 influences cellular signal transduction and ion transport.

**Health Implications**
- Enhanced G-protein activation with increased signal transduction
- Increased risk of essential hypertension, atherosclerosis, MI, and LVH
- Increased risk of obesity, insulin resistance, and depression.

**Treatment Options**
- Favorable BP response to clonidine, thiazide diuretics, calcium channel-blockers, and sodium restriction; also *Taraxacum* (dandelion)
- Nitroglycerin produces greater venodilation
- Greater immune response to Hepatitis B vaccination, Hepatitis C response to interferon(a)/ribavirin, and anti-retroviral therapy in HIV.
- Favorable response to anti-depressant treatment, regardless of class
- Greater erectile response to sildenafil (Viagra®)
### AGTR1

**Location:**
- Chromosome 3
- A1166C

**Your Genotype:**
- [ ]
- [ ]

**Angiotensin II Receptor-1 - HYPERTENSION**

AGTR1 mediates the effects of angiotensin II including: contractility, vasoconstriction, vascular hypertrophy, inflammation & oxidative stress.

**Health Implications**
- Reduced risk of HTN, coronary artery disease and kidney disease (HTN): slower disease progression in chronic renal disease.

**Treatment Options:**
- Less reduction in arterial stiffness with ACE inhibitors, but most favorable response to calcium channel blockers
- Nutrients that minimize the effects of AGT II include: fish oils, borage seed oil, magnesium, potassium, L-arginine and taurine.

### GP3A PL(A)

**Location:**
- Chromosome 17
- PL(A1)/ PL(A2)

**Your Genotype:**
- [ ]
- [ ]

**Platelet Glycoprotein IIIa - COAGULATION**

GP3A is a protein component of the platelet fibrinogen receptor IIbIIIa, playing a pivotal role in platelet aggregation and thrombus formation.

**Health Implications**
- Decreased platelet aggregability and decreased risk of clot formation
- Greater risk of perioperative bleeding due to longer bleeding time

**Treatment Options**
- Aspirin and oral platelet antagonists are most effective in this genotype
- This genotype may be less sensitive to platelet - inhibiting effects of estrogen

---

The GP3A polymorphism is a L33P change that results from the substitution of cytosine for thymidine at position 1565. Clinical studies commonly refer to this change as PL(A1) -> PL(A2).
### FACTOR V

**Location:**
Chromosome 1

**R506Q**

**Your Genotype:**

<table>
<thead>
<tr>
<th>4G</th>
<th>5G</th>
</tr>
</thead>
</table>

Factor V combines with Factor X to convert prothrombin to thrombin, the essential part of a blood clot. Factor Va is held in check by Protein C.

**Health Implications**
- Normal inactivation of Factor V by activated Protein C
- No increased risk of venous thromboembolism

**Treatment Options**
- None indicated

---

### FACTOR II

**Location:**
Chromosome 11

**G20210A**

**Your Genotype:**

<table>
<thead>
<tr>
<th>4G</th>
<th>5G</th>
</tr>
</thead>
</table>

Factor II is also known as prothrombin, which is converted to its active form, thrombin, and forms the essential part of a blood clot.

**Health Implications**
- Normal levels of prothrombin
- No increased risk of venous thromboembolism

**Treatment Options**
- None indicated

---

### PAI-1

**Location:**
Chromosome 7

**Del/Ins (4G/5G)**

**Your Genotype:**

4G  5G

The PAI-1 polymorphism represents a single base-pair guanine (hence 5G->4G) in the promoter region. 5G is the norm and 4G is the variant or polymorphism.

PAI-1, present in platelets and vascular endothelium, decreases activation of plasminogen, inhibiting fibrinolytic activity and increasing clots.

**Health Implications**
- Higher PAI-1 levels and moderately increased risk of thrombosis
- Possible increased risk of periodontitis, asthma and allergic disease, and PCOS
- Slightly increased risk of obesity, especially in post-menopausal women

**Treatment Options**
- Evaluate insulin resistance; thiazolidinediones and metformin tend to reduce PAI-1
- PAI-1 is reduced by weight reduction and regular exercise
- Avoid smoking, which increases PAI-1 and risk of restenosis
- Minimize stressors, high intake of saturated fat, and alcohol
- ARBs reduce PAI-1 levels and ACE inhibitors are particularly effective in hypertensive patients with genotype
- Hormone therapy and DHEA supplementation reduces PAI-1, decreasing clots post-menopausally
- Nattokinase dissolves fibrin and inactivates PAI-1

---

© Genova Diagnostics · CLIA Lic. #34D0655571 · Medicare Lic. #34-8475
This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration.

Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner.

The accuracy of genetic testing is not 100%. Results of genetic tests should be taken in the context of clinical representation and familial risk. The prevalence and significance of some allelic variations may be population specific.

Any positive findings in your patient's test indicate genetic predisposition that could affect physiologic function and risk of disease. We do not measure every possible genetic variation. Your patient may have additional risk that is not measured by this test. Negative findings do not imply that your patient is risk-free.

The Third Wave™ Invader DNA assay is used to detect polymorphisms in the patient's DNA sample. In this assay, a solution hybridization method is used in which two oligonucleotides hybridize in tandem with the specific DNA sequences. Subsequent Cleavase® and hybridization reactions result in generation of fluorescent signal. The biplex format of the assay enables simultaneous detection of all variants in a single reaction tube.